About – Douglas Berger Psychiatrist Tokyo


Dr. Douglas Berger, M.D., Ph.D., Meguro Counseling Center Director

Dr. Berger came to Japan as a medical exchange student and psychiatric researcher at the Tokai University School of Medicine on a research fellowship from the Matsumae International Foundation. He later returned to Japan to do further psychiatric research at the Tokyo University Department of Psychosomatic Medicine and the Tokyo Institute of Psychiatry. Dr. Berger speaks native-level Japanese and regularly conducts psychotherapy for mixed-cultural couples as well as the local Japanese community. This page lists Dr. Berger’s research activity, and this page is an archive of community education articles for the Tokyo Families Magazine written by Dr. Berger. Dr. Berger also works extensively with children as Director of the Tokyo Child & Adolescent Counseling Service. Dr. Berger is a legal permanent resident of Japan.

Douglas Berger is a now a fully bilingual American board certified psychiatrist, is the Director of the Tokyo Meguro Counseling Center. Douglas Berger is a M.D., and a Ph.D. Dr.  Berger is a graduate of New York Medical College where he completed a 4-year residency program in psychiatry. He then finished a fellowship in Psychosomatic Medicine at the Albert Einstein College of Medicine. Now based in Tokyo, he had served on the Faculty of the Albert Einstein College of Medicine Department of Psychiatry in New York as an Assistant Professor of Psychiatry and licensed practicing U.S. physician. Dr. Berger’s Japanese qualifications include a Ph.D. from the University of Tokyo School of Medicine received for psychiatric research done while at the Tokyo University Department of Psychosomatic Medicine.

Credential Verifications

Dr. Berger’s medical degree is from the United States, he is well-versed in the use of psychiatric medication and can guide the use of psychiatric medications integrated with psychotherapy through the physicians affiliated with his counseling practice (he does not directly practice medical care in Japan). Further information on Dr. Berger can be seen on his personal home page.

Publications by Dr. Douglas Berger, psychiatrist in Tokyo

Berger D: DOUBLE BLINDING REQUIREMENT FOR VALIDITY CLAIMS IN COGNITIVE-BEHAVIORAL THERAPY INTERVENTION TRIALS FOR MAJOR DEPRESSIVE DISORDER. Analysis of Hollon S, et al., Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial, F1000Research 2015, 4:639 (doi: 10.12688/f1000research.6954.1). U.S. National Library of Medicine version.

Berger D: DOUBLE-BLINDING AND BIAS IN MEDICATION AND COGNITIVE-BEHAVIORAL THERAPY TRIALS FOR MAJOR DEPRESSIVE DISORDER, F1000Research 2016, 4:638 (doi: 10.12688/f1000research.6953.2). U.S. National Library of Medicine version.

Articles by Douglas Berger, M.D., Ph.D. for Tokyo Families magazine.

Click here to see a full list of articles.

For more information on Dr. Doug Berger, read some of the articles here.

To contact Douglas Berger psychiatrist Tokyo and set up an appointment, click here.

Neuro-chemicals of persons with psychosis is abnormal: https://t.co/mN0RYEq9W5. That biochemical abnormalities exist in psychosis is strong: https://t.co/lg4v2j3SYa. Many psychiatrists are calling for an overhaul of the bio-psycho-social model. Us: https://t.co/Fp4G4mtROK

iGen or the ("Internet Generation) is said to have a correlation of time on digital media and mental problems: https://t.co/C3wb1H6jUh. Public shaming has more real-life negatives than just one's thoughts. Us: https://t.co/zoQhPY52RF

Encapsulated cells may escape immune rejection: https://t.co/VUld071QK7. They can secrete molecules to treat many illnesses like diabetes, scarring, hemophilia, glaucoma, and others. Us: https://t.co/WGBeQYN1YA

Octopuses given MDMA-Ecstasy-began to act in-love with other octopuses: https://t.co/jU6aAhbNj6. This suggests that human brain regions that produce this behavior wasn't developed until much later because Octopuses do not have these areas developed. Us: https://t.co/edDvtd6zbo

Amber lens therapy is said to “work” for bipolar disorder: https://t.co/DA8sEQSSzN But this is only a preliminary unblinded case series with no blind placebo control. It is not yet valid to say Amber lens therapy works for bipolar disorder. Us: https://t.co/We7OmvxoYF

Load More...

Stimulation of the Vagus & other nerves are treating headaches, opioid withdrawal, & possibly autoimmune-related diseases: https://t.co/oM6XLNcvCg. The future of this modality is fascinating. Us: https://t.co/K330lNOED8

AI is helping screen for potential for new drugs: https://t.co/Vzrg9QLxAs. AI helps go thru the vast possible molecules via "virtual libraries" of drug structures and properties. Great hope for the future. Us: https://t.co/QzztBjh4ck

A Chinese study looked at ADHD risk w/diet. High minerals/protein (m/p) gave 47% reduced risk of ADHD: https://t.co/vFAigpgqZT, 57% of low m/p had ADHD vs 39% of high m/p w/ADHD. 39% is still 68% of the 57%, so 68% on high m/p still had ADHD. Us: https://t.co/GwwzyYyjaI

There are no biologically measurables for psychiatric diagnoses: https://t.co/YDUdkfEHwB. There is considerable overlap between criteria sets & even the DSMs do not purport to classify conditions based on etiology much less objective measures. Us: https://t.co/03IryHDFhX

DSM classifications attempt to avoid under or over diagnosing, reimbursement & special interest groups: https://t.co/YDUdkfEHwB. Diagnostic names change over the generations of new DSMs with little concern for diagnostic validity. Us: https://t.co/QzztBjh4ck

Load More...